SELECT study of daclizumab High Yield (Biogen) for MS published in The Lancet
Biogen Idec has announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as an online article in The Lancet. SELECT was a Phase IIb study designed to determine the efficacy and safety of DAC HYP in patients with relapsing-remitting multiple sclerosis.
Published results demonstrate that both 150 mg and 300 mg subcutaneous injections of DAC HYP, administered once every four weeks, met the study�s primary endpoint by significantly reducing annualized relapse rate (ARR) by 54 percent (p<0.0001) and 50 percent (p="0.0002)," respectively, compared to placebo at one year. in addition, results demonstrated that dac hyp reduced multiple sclerosis (ms) brain lesions compared to placebo.>
see -The Lancet, Early Online Publication, 4 April 2013- doi:10.1016/S0140-6736(12)62190-4 -"Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial." Prof Ralf Gold MD ,Prof Gavin Giovannoni PhD , Prof Krzysztof Selmaj MD et al., for the SELECT study investigators.
160 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.